Arvinas Inc represents values of innovation, integrity, and commitment to advancing healthcare through targeted protein degradation. The company's corporate philosophy focuses on developing novel therapeutics using their proprietary PROTAC® platform. Arvinas Inc strives to discover and deliver transformative medicines that address significant unmet medical needs. By harnessing the power of protein degradation, Arvinas Inc aims to revolutionize the treatment of diseases such as cancer and other serious conditions. Through their cutting-edge research and dedication to improving patients' lives, Arvinas Inc continues to be a leader in the field of targeted protein degradation.

Arvinas Inc is primarily present in the United States.

Arvinas Inc, a leading biotechnology company, has achieved several significant milestones. The company successfully developed and secured approval for its lead product candidate, ARV-110, which targets the androgen receptor protein for the treatment of metastatic castration-resistant prostate cancer. Arvinas has also advanced its second program, ARV-471, for the treatment of breast cancer, into clinical trials. Furthermore, the company has entered into strategic collaborations with leading pharmaceutical companies to expand the application of its PROTAC® technology platform. Arvinas' dedication to innovative drug development and strategic partnerships showcases its commitment to revolutionizing the field of targeted protein degradation.

Arvinas Inc, founded in 2013, is a biopharmaceutical company based in New Haven, Connecticut. The company focuses on developing targeted protein degradation therapies to treat various diseases such as cancer and genetically driven conditions. Arvinas utilizes its proprietary PROTAC® (PROteolysis TArgeting Chimeras) platform, allowing selective protein degradation and removal from cells. This innovative approach offers the potential for more effective and precise treatments. Arvinas has partnered with pharmaceutical companies and has a diverse pipeline targeting different diseases. With its cutting-edge technology and strategic partnerships, Arvinas aims to revolutionize the field of protein degradation therapy for the benefit of patients worldwide.

Some of the main competitors of Arvinas Inc. in the market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, and Pfizer Inc.

Arvinas Inc is primarily active in the biotechnology industry.

The business model of Arvinas Inc revolves around developing and commercializing protein degradation therapies for various diseases. By leveraging their proprietary PROTAC® (PROteolysis-TArgeting Chimeras) platform, Arvinas aims to address diseases that traditional small molecules and biologics struggle to target effectively. This innovative approach targets disease-causing proteins for degradation, which can potentially lead to more efficient and precise treatments. Arvinas focuses on collaborations with pharmaceutical partners to advance their product pipeline and expand their reach in therapeutic areas such as oncology, neurology, and rare diseases. With their cutting-edge technology and strategic partnerships, Arvinas Inc strives to provide breakthrough therapies for patients in need.

KGV Arvinas iznosi −4,47.

Koeficijent cijene i prometa Arvinas iznosi 8,33.

AlleAktien Qualitätsscore za Arvinas je 4/10.

Promet očekivana Arvinas iznosi 162,86 mil. USD.

Dobit očekivana Arvinas iznosi −303,15 mil. USD.

Arvinas Inc is a biotechnology company based in New Haven, Connecticut, USA. They specialize in the development of therapeutics based on protein degradation. Their goal is to treat diseases that traditional approaches, such as enzyme inhibition or receptor blockade, are not sufficient for. The basic principle of protein degradation is to specifically break down faulty or diseased proteins by targeting them. Arvinas focuses on the development of PROTACs (Proteolysis-Targeting Chimeras), which consist of two binding molecules. One molecule binds to the faulty protein, while the other molecule marks it for degradation by the body's own proteasome. Arvinas' core areas include oncology, neurodegeneration, inflammatory diseases, and rare genetic disorders. By manipulating proteins, they potentially can develop individualized treatment approaches for each disease. In oncology, Arvinas is focused on developing therapeutics for breast cancer, prostate cancer, and lung cancer. In neurodegeneration, their aim is to effectively combat Alzheimer's, Parkinson's, or ALS. In inflammation research, their focus is on rheumatoid arthritis and fibrosis. Arvinas has recently entered into partnerships with leading pharmaceutical companies. They are working with Pfizer on the development of immuno-oncology therapeutics. Another partnership exists with Genentech, a sister company of Roche, for the discovery and development of therapeutics in the field of neurodegeneration. However, Arvinas is not only involved in drug development but also offers research services for PROTAC development. They explore new target molecules and develop specific PROTACs for pharmaceutical industry clients. This is an important growth market for the company as more companies recognize the advantages of protein degradation as a therapeutic approach. Another significant growth field for Arvinas is the use of "traps." These are synthetic molecules that mark and intercept faulty proteins before they reach their target location. Arvinas has developed their own technologies for this and has already achieved initial successes, particularly in cancer treatment. Overall, Arvinas Inc is a promising biotechnology company with a broad pipeline of therapeutics based on protein degradation. With strong partnerships with various companies and an open research infrastructure, they will be able to continue their research and development of therapeutics for a variety of diseases.

Arvinas isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Arvinas trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Arvinas je US04335A1051.

WKN od Arvinas je A2N6VP.

Oznaka burze tvrtke Arvinas je ARVN.

U posljednjih 12 mjeseci Arvinas je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Arvinas će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Arvinas iznosi .

Arvinas isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Arvinas je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Arvinas se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Arvinas od 23. 08. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 23. 08. 2024..

Posljednja isplata dividende izvršena je 23. 08. 2024..

U godini 2023 su od Arvinas 0 USD isplaćene kao dividende.

Dividende od Arvinas isplaćuju se u USD.